Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab With Cetuximab in Locally Advanced Resectable Oral Squamous Cell Carcinoma
NCT07882888Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Major Pathological Response rate at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07882888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882888.